Patents Assigned to Copernicus Therapeutics, Inc.
-
Patent number: 9486540Abstract: Disclosed herein are methods and compositions for the treatment of diseases of the CNS with nucleic acid nanoparticles. Compositions are also disclosed herein that utilize nucleic acid nanoparticles to treat conditions such as Parkinson's Disease. Furthermore, methods of intranasally administering the compacted nucleic acid nanoparticles for therapeutic purposes in the brain are disclosed.Type: GrantFiled: March 11, 2013Date of Patent: November 8, 2016Assignees: Northeastern University, Copernicus Therapeutics, Inc.Inventors: Brendan Harmon, Barbara Lee Waszczak, Mark Cooper
-
Patent number: 8389238Abstract: Efficient and prolonged hCFTR expression is one of the major obstacles for cystic fibrosis lung therapy. hCFTR mRNA expression levels depend on eukaryotic expression cassette components, prokaryotic backbone elements, and the gene transfer method may also influence transcriptional silencing mechanisms. A codon-optimized and CpG-reduced human CFTR gene (CO-CFTR) was made. Various vector modifications were tested to facilitate extended duration of CO-CFTR expression. Insertion of an extended 3?BGH transcribed sequence (712 bp) in an inverted orientation produced prolonged expression of CO-CFTR expression at biologically relevant levels. Further studies revealed that prolonged CO-CFTR expression is dependant on the orientation of the extended BGH 3? BGH transcribed sequence and its transcription, is not specific to the UbC promoter, and is less dependent on other vector backbone elements.Type: GrantFiled: September 12, 2008Date of Patent: March 5, 2013Assignee: Copernicus Therapeutics, Inc.Inventors: Mark J. Cooper, Linas Padegimas
-
Patent number: 8017577Abstract: Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to measure is the turbidity parameter. Shape also affects the suitability and efficacy of compacted nucleic acid complexes for transfecting cells by various routes into a mammalian body. Moreover, counterions such as acetate can protect compacted nucleic acid complexes from adverse effects of lyophilization.Type: GrantFiled: September 8, 2003Date of Patent: September 13, 2011Assignee: Copernicus Therapeutics, Inc.Inventors: Mark J. Cooper, Murali K. Pasumarthy, Tomasz H. Kowalczyk, Maureen Costello
-
Publication number: 20110035819Abstract: A synthetic hCFTR DNA sequence has been developed that produces remarkably high levels of hCFTR mRNA and protein in dosed murine lungs and human cells in culture compared to the natural hCFTR cDNA. This synthetic DNA addresses problems inherent in some natural cDNAs, such as premature transcriptional truncation sites introduced during cDNA synthesis. Introns are initially present in mRNA until the mRNA is processed. cDNA made from processed mRNA is devoid of introns. Thus DNA sequences (exon junctions) are present in a cDNA molecule which are not present in cells in nature. These exon junctions may affect transcription. Methods for improving expression of CFTR are based on sequence changes in cDNA molecules. The improvement methods may be applied to other cDNA molecules which are refractory to in vivo expression efforts. Compositions embodying the sequence changes increase the production of both transgenic mRNA and protein from cDNA molecules.Type: ApplicationFiled: October 12, 2007Publication date: February 10, 2011Applicant: COPERNICUS THERAPEUTICS INC.Inventors: Mark J. Cooper, Linas Padegimas
-
Publication number: 20100203627Abstract: Efficient and prolonged hCFTR expression is one of the major obstacles for cystic fibrosis lung therapy. hCFTR mRNA expression levels depend on eukaryotic expression cassette components, prokaryotic backbone elements, and the gene transfer method may also influence transcriptional silencing mechanisms. A codon-optimized and CpG-reduced human CFTR gene (CO-CFTR) was made. Various vector modifications were tested to facilitate extended duration of CO-CFTR expression. Insertion of an extended 3?BGH transcribed sequence (712 bp) in an inverted orientation produced prolonged expression of CO-CFTR expression at biologically relevant levels. Further studies revealed that prolonged CO-CFTR expression is dependant on the orientation of the extended BGH 3? BGH transcribed sequence and its transcription, is not specific to the UbC promoter, and is less dependent on other vector backbone elements.Type: ApplicationFiled: September 12, 2008Publication date: August 12, 2010Applicant: COPERNICUS THERAPEUTICS, INC.Inventors: Mark J. Cooper, Linas Padegimas
-
Publication number: 20040048787Abstract: Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to measure is the turbidity parameter. Shape also affects the suitability and efficacy of compacted nucleic acid complexes for transfecting cells by various routes into a mammalian body.Type: ApplicationFiled: September 8, 2003Publication date: March 11, 2004Applicant: Copernicus Therapeutics, Inc.Inventors: Mark J. Cooper, Murali K. Pasumarthy, Tomasz H. Kowalczyk, Maureen Costello
-
Publication number: 20030171322Abstract: Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to measure is the turbidity parameter. Shape also affects the suitability and efficacy of compacted nucleic acid complexes for transfecting cells by various routes into a mammalian body.Type: ApplicationFiled: December 2, 2002Publication date: September 11, 2003Applicant: Copernicus Therapeutics, Inc.Inventors: Mark J. Cooper, Murali K. Pasumarthy, Tomasz H. Kowalczyk, Maureen Costello
-
Publication number: 20030134818Abstract: Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to measure is the turbidity parameter. Shape also affects the suitability and efficacy of compacted nucleic acid complexes for transfecting cells by various routes into a mammalian body.Type: ApplicationFiled: December 2, 2002Publication date: July 17, 2003Applicant: Copernicus Therapeutics, Inc.Inventors: Mark J. Cooper, Murali K. Pasumarthy, Tomasz H. Kowalczyk, Maureen Costello
-
Publication number: 20030078229Abstract: Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to measure is the turbidity parameter. Shape also affects the suitability and efficacy of compacted nucleic acid complexes for transfecting cells by various routes into a mammalian body.Type: ApplicationFiled: November 27, 2002Publication date: April 24, 2003Applicant: Copernicus Therapeutics, Inc.Inventors: Mark J. Cooper, Murali K. Pasumarthy, Tomasz H. Kowalczyk, Maureen Costello
-
Publication number: 20030078230Abstract: Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to measure is the turbidity parameter. Shape also affects the suitability and efficacy of compacted nucleic acid complexes for transfecting cells by various routes into a mammalian body.Type: ApplicationFiled: November 27, 2002Publication date: April 24, 2003Applicant: Copernicus Therapeutics, Inc.Inventors: Mark J. Cooper, Murali K. Pasumarthy, Tomasz H. Kowalczyk, Maureen Costello
-
Patent number: 6281005Abstract: An automated nucleic acid compaction device for analyzing and compacting a nucleic acid complex into unimolecular nucleic acid particles. Broadly, the device includes a container support and agitation system; a measuring and testing system; and a dispensing system; all controlled by a control system. The control system controls the support and agitation system and the dispensing system based either on a predetermined formulation or by analysis of feedback data provided by the measuring and testing system. In a preferred embodiment, the device is a real-time measuring and mixing instrument operating in a closed loop system. The preferred embodiment also comprises a monitoring system including a submersible probe which is positioned in the batch solution to provide data to a controller. Once a desired level of nucleic acid compaction is reached, as detected by the monitoring system, the controller stops the dispensing and mixing agitating systems.Type: GrantFiled: May 14, 1999Date of Patent: August 28, 2001Assignee: Copernicus Therapeutics, Inc.Inventors: Hector L. Casal, Mark J. Cooper, Tomasz H. Kowalczyk, Murali Krishna Pasumarthy, Jose C. Perales, Steven J. Torontali